Side effects presented as early as 1 week after beginning therapy, with a mean time of onset of 12.6 weeks in our cohort. This study was limited by the small number of cases, all from a single institution. Selective BRAF inhibitor therapy is associated with the development of malignant and ...
a small-molecule inhibitor the company licensed from NeuPharma, to be investigated in Phase 1b/2 clinical trials as monotherapy or in combination therapy for the treatment of BRAF V600E or BRAF V600 mutation
Studies about BRAF kinase inhibitor bearing imidazo[4,5-b]pyridines were categorized in two groups: (1) 2,5-disubstituted imidazopyridines were Type-I BRAF inhibitors, which interacted with the kinase in its active state (DFG-in), and a hydrogen bond was formed between imidazopyridine and Cys...
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated wh... A Lassen,M Atefi,L Robert,... - 《Molecular...
A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with...
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265–1272. 49. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with ...
Additionally, zeaxanthin sensitized A2058 melanoma cells in vitro to the cytotoxic activity of vemurafenib, a BRAF inhibitor widely used for the clinical management of melanoma, suggesting its potential interest as dietary adjuvant increasing melanoma cells sensitivity to chemotherapy....
Prior to the assay, the inhibitor was either heated for 30 min at 60 °C to fully thermally adapt to the trans isomer or irradiated with 365 nm light for 45 min to reach PSS (see Table 1). First, the IC50 values of the reference compounds Discussion In the emerging field ...
The BRAF gene is involved in tellinghealthy cellswhen to grow and form new cells, but it is also known to go wrong, or mutate, in several types ofcancer, including types of bowel, brain and skin cancer. A few BRAF inhibitor drugs have already proved effective in treating patients. However...
A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereo